Table 2.

Important trials supporting individualized therapy—as-needed and treat and extend—for the treatment of neovascular age-related macular degeneration are listed. Important design characteristics and top-end results are included. BCVA = best corrected visual acuity; CNVM = choroidal neovascularization; PDT = photodynamic therapy; wk = week; PRN = as needed.

Drugs and Trials	Important Findings
PRN Trials
Ranibizumab (Lucentis®)  PrONTO  SAILOR  EXTEND-I  SUSTAIN  HORIZON	• Mean 1-year BCVA improvement: +9.3 letters • 35% improved by at least 3 lines • Average number of injections over 2 years: 9.9 • BCVA decreased from +5.8 and +7.0 letters (after 3 monthly injections)  to +0.5 and +2.3 letters (1 year) • 19.2% of patients improved by at least 15 letters • Average BCVA at 1 year: +9.5 and +10.5 letters • 31% and 37% improved by 15 letters • Intravitreal t½ of 6.5 to 7.85 days • Monthly injections × 3 then PRN • Average 12-month BCVA: +3.6 letters • Average injections in final 9 months: 2.7 • Continuation of patients treated in MARINA, ANCHOR & FOCUS • Average injections at 1, 2, 3 years: 2.2, 4.2, 4.3
Ranibizumab and  Bevacizumab (Avastin®)  (Subramanian et al)  CATT  IVAN  MANTA  GEFAL	• Average 6-monthV A improvements:  Bevacizumab: +14.8 letters  Ranibizumab: +7.0 letters (p = 0.09) • 12-month BCVA:  Bevacizumab monthly: +8.0 letters  Ranibizumab monthly: +8.5 letters  Bevacizumab PRN: +5.9 letters  Ranibizumab PRN: +6.8 letters • Average PRN injections: bevacizumab (7.77), ranibizumab (6.9) • 12-month BCVA: bevacizumab − ranibizumab = −1.99 letters • 12-month BCVA: discontinuous − continuous = −0.35 letters • 12-month BCVA: Bevacizumab (+4.9 letters)  Ranibizumab (+4.1 letters) • 12-month BCVA:  Bevacizumab (+5.4 letters)  Ranibizumab (+3.6 letters)
Treat and Extend Trials
Engelbert et al. Gupta et al. LUCAS		• Average LogMAR BCVA improved by 0.01 at 24 months • Average BCVA improved from 20/135 to 20/83 at 2 years • Mean numbers of injections were 8.36 (1 year) and 7.45 (2 years) • 12-month BCVA:  Bevacizumab (+8.0 letters)  Ranibizumab (+8.2 letters)